ImVisioN Therapeutics Starts Phase I Clinical Trial Of IVN201 Against Cat Dander Allergy And Raises CHF 4.6 M
ImVisioN Therapeutics AG., a biopharmaceutical company pioneering intralymphatic immunotherapy (ILIT™), announced that it has enrolled the first patient for a Phase I clinical study of its lead product IVN201, an immunotherapeutic product for